128 related articles for article (PubMed ID: 28100394)
21. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
22. SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.
Stadler J; Eder J; Pratscher B; Brandt S; Schneller D; Müllegger R; Vogl C; Trautinger F; Brem G; Burgstaller JP
PLoS One; 2015; 10(11):e0142273. PubMed ID: 26562020
[TBL] [Abstract][Full Text] [Related]
23. Replication Study: Intestinal inflammation targets cancer-inducing activity of the microbiota.
Eaton K; Pirani A; Snitkin ES;
Elife; 2018 Oct; 7():. PubMed ID: 30295289
[TBL] [Abstract][Full Text] [Related]
24. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Laugier F; Finet-Benyair A; André J; Rachakonda PS; Kumar R; Bensussan A; Dumaz N
Oncotarget; 2015 Sep; 6(29):28120-31. PubMed ID: 26356562
[TBL] [Abstract][Full Text] [Related]
25. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.
Vujic I; Sanlorenzo M; Esteve-Puig R; Vujic M; Kwong A; Tsumura A; Murphy R; Moy A; Posch C; Monshi B; Rappersberger K; Ortiz-Urda S
Oncotarget; 2016 Feb; 7(6):7297-306. PubMed ID: 26771141
[TBL] [Abstract][Full Text] [Related]
26. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
Salgado CM; Basu D; Nikiforova M; Hamilton RL; Gehris R; Jakacki R; Panigrahy A; Yatsenko S; Reyes-Múgica M
Melanoma Res; 2015 Oct; 25(5):453-60. PubMed ID: 26266759
[TBL] [Abstract][Full Text] [Related]
27. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
28. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
29. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
30. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
31. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
32. Clonal architectures and driver mutations in metastatic melanomas.
Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
[TBL] [Abstract][Full Text] [Related]
33. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
34. Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells.
Albinet V; Bats ML; Huwiler A; Rochaix P; Chevreau C; Ségui B; Levade T; Andrieu-Abadie N
Oncogene; 2014 Jun; 33(26):3364-73. PubMed ID: 23893239
[TBL] [Abstract][Full Text] [Related]
35. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract][Full Text] [Related]
36. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
37. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
38. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
[TBL] [Abstract][Full Text] [Related]
39. Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.
Essex A; Pineda J; Acharya G; Xin H; Evans J;
Elife; 2019 Jun; 8():. PubMed ID: 31215867
[TBL] [Abstract][Full Text] [Related]
40. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]